Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs
Authors
- Yang Lu (ORCID: https://orcid.org/0000-0002-1913-061X)
- Yongkun Sun
- Jiang Zhu (ORCID: https://orcid.org/0000-0003-3519-0062)
- Caifeng Gong (ORCID: https://orcid.org/0000-0002-1864-8206)
- Dandan Cao (ORCID: https://orcid.org/0009-0003-9705-133X)
- Jinglong Huang (ORCID: https://orcid.org/0000-0002-9729-7079)
- Qi Cai
- Te Liu
- Wei Wang
- Aiping Zhou
- Shuhui You
- Hong Zhao
- Wen Zhang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/17588359251407052
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00